Centessa Pharmaceuticals (CNTA) Cash from Financing Activities (2020 - 2026)

Centessa Pharmaceuticals (CNTA) has 7 years of Cash from Financing Activities data on file, last reported at $30.5 million in Q1 2026.

• Quarterly Cash from Financing Activities rose 887.27% year-over-year to $30.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $318.9 million (down 10.76% YoY) and the FY2025 annual result came in at $291.5 million, down 20.08% from the prior year.
• Cash from Financing Activities fell to $30.5 million in Q1 2026 per CNTA's latest filing, from $283.4 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $283.4 million in Q4 2025 and bottomed at $12000.0 in Q2 2023.
• The 5-year median for Cash from Financing Activities is $3.3 million (2025), against an average of $44.3 million.
• The widest annual swing landed in 2022, when Cash from Financing Activities tumbled 99.98%; it then soared 877508.33% in 2024.
• Tracing CNTA's Cash from Financing Activities over 5 years: stood at $89000.0 in 2022, then soared by 7047.19% to $6.4 million in 2023, then tumbled by 53.42% to $3.0 million in 2024, then jumped by 9464.63% to $283.4 million in 2025, then sank by 89.25% to $30.5 million in 2026.
• Per Business Quant, the three latest CNTA Cash from Financing Activities figures stand at $30.5 million (Q1 2026), $283.4 million (Q4 2025), and $3.4 million (Q3 2025).

Peer Comparison